Key statistics dashboard for Nexalin Technology, Inc. (NXL). Valuation multiples (P/E, P/B, EV/EBITDA), profitability margins, financial-health ratios, per-share metrics and stock-level data in one consolidated view — the snapshot quantitative analysts and value investors check first.
Nexalin Technology, Inc. operates as a medical device firm specializing in the creation and advancement of neurostimulation therapies for mental health conditions in both the United States and China. The company commercializes its primary product, the Nexalin Device, which provides a non-invasive and drug-free treatment for anxiety and insomnia.
Stock Data
| Price | $4.92 |
| Market Cap | $4M |
| Beta | 4.23 |
| Exchange | NASDAQ |
| Country | US |
Valuation Multiples
| P/E Ratio | -0.34 |
| Price / Book | 2.28 |
| P/S | 16.62 |
| P/FCF | -0.58 |
| Dividend Yield | 0.00% |
Profitability
| Gross Margin | -148.42% |
| EBIT Margin | -4139.38% |
| EBITDA Margin | -4129.03% |
| Operating Margin | -4202.54% |
| Net Margin | -4139.38% |
Financial Health
| Current Ratio | 1.25 |
| Quick Ratio | 1.10 |
| Cash Ratio | 0.68 |
| Debt / Equity | 0.00 |
| Debt / Assets | 0.00% |
| Interest Coverage | 0.00 |
| Piotroski F-Score | 3 |
| Altman Z-Score | -26.89 |
Per-Share Data
| Revenue per share | 0.31 |
| Book Value per share | 2.16 |
| Cash per share | 1.43 |
| FCF per share | -8.81 |
| Tangible Book Value per share | 2.16 |
| Dividend per share | 0.00 |
Analyst Consensus
| Strong Buy | 0 |
| Buy | 1 |
| Hold | 0 |
| Sell | 0 |
| Strong Sell | 0 |
| Total analysts | 1 |
| Avg rating (1-5) | 1.00 |
Related companies: CLGN · ENLV · HBIO · IINN · MODD · NRXS · RBOT
Explore sector: Healthcare · Medical - Devices
More sections of NXL: Overview · Financials · Valuation · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks